内科理论与实践2026，Vol.21Issue(1)：59-61,3.DOI:10.16138/j.1673-6087.2026.01.08
奥雷巴替尼联合奥加伊妥珠单抗治疗多次复发Ph阳性急性淋巴细胞白血病1例
Olverembatinib combined with inotuzumab ozogamicin in Philadelphia chromosome-positive acute lymphoblastic leukemia with multiple relapses:a case report
摘要
Abstract
Relapsed/refractory(R/R)Philadelphia chromosome-positive acute lymphoblastic leukemia(Ph+ALL)is difficult to treat,facing a poor prognosis and short overall survival.The usage of tyrosine kinase inhibitor(TKI)and immunotherapy has brought new hope for the treatment of R/R Ph+ALL for patients.This paper retrospectively analyzed a patient with Ph+ALL experiencing multiple relapses,who was treated with olverembatinib in combination with a reduced dose of inotuzumab ozogamicin.The patient achieved complete response(CR)and minimal residual disease(MRD)negativity upon reexamination two months later,attaining a near-complete molecular response(CMR).A review of relevant literature is included to provide clinical treatment experience.关键词
奥雷巴替尼/奥加伊妥珠单抗/复发难治/费城染色体阳性急性淋巴细胞白血病Key words
olverembatinib/inotuzumab ozogamicin/relapsed/refractory/Philadelphia chromosome-positive acute lymphoblastic leukemia分类
医药卫生引用本文复制引用
刘恒,葸瑞,潘耀柱,王宗慧,田红娟,毛东锋,吴涛..奥雷巴替尼联合奥加伊妥珠单抗治疗多次复发Ph阳性急性淋巴细胞白血病1例[J].内科理论与实践,2026,21(1):59-61,3.基金项目
兰州市青年科技人才创新项目(2023-QN-16) （2023-QN-16）
甘肃省重点研发计划(22YF7FA106) （22YF7FA106）
联勤保障部队第九四〇医院血液病医学研究中心项目(2021yxky078) （2021yxky078）
甘肃省科技计划项目(21JR7RA015、22YF7FA106、23JRRA535、25JRRA1184) （21JR7RA015、22YF7FA106、23JRRA535、25JRRA1184）
